- Home
- GTE vs AMRN Comparison
GTE vs AMRN Comparison
Compare GTE & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- AMRN
- Stock Information
- Founded
- GTE 2003
- AMRN 1989
- Country
- GTE Canada
- AMRN Ireland
- Employees
- GTE N/A
- AMRN N/A
- Industry
- GTE Oil & Gas Production
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- AMRN Health Care
- Exchange
- GTE Nasdaq
- AMRN Nasdaq
- Market Cap
- GTE 253.1M
- AMRN 234.4M
- IPO Year
- GTE N/A
- AMRN 1993
- Fundamental
- Price
- GTE $6.77
- AMRN $0.59
- Analyst Decision
- GTE Hold
- AMRN Hold
- Analyst Count
- GTE 1
- AMRN 3
- Target Price
- GTE $10.00
- AMRN $1.00
- AVG Volume (30 Days)
- GTE 337.3K
- AMRN 663.0K
- Earning Date
- GTE 10-29-2024
- AMRN 10-30-2024
- Dividend Yield
- GTE N/A
- AMRN N/A
- EPS Growth
- GTE 7.45
- AMRN N/A
- EPS
- GTE 1.56
- AMRN N/A
- Revenue
- GTE $658,051,000.00
- AMRN $264,779,000.00
- Revenue This Year
- GTE $11.16
- AMRN N/A
- Revenue Next Year
- GTE $20.54
- AMRN N/A
- P/E Ratio
- GTE $4.28
- AMRN N/A
- Revenue Growth
- GTE 3.94
- AMRN N/A
- 52 Week Low
- GTE $4.72
- AMRN $0.56
- 52 Week High
- GTE $10.40
- AMRN $1.37
- Technical
- Relative Strength Index (RSI)
- GTE 46.20
- AMRN 45.80
- Support Level
- GTE $6.07
- AMRN $0.56
- Resistance Level
- GTE $6.40
- AMRN $0.59
- Average True Range (ATR)
- GTE 0.31
- AMRN 0.02
- MACD
- GTE 0.12
- AMRN 0.00
- Stochastic Oscillator
- GTE 68.33
- AMRN 36.78
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. It is engaged in the acquisition, exploration, development, and production of oil and gas properties. The firm produces light crude oil, supplemented with medium crude and natural gas. Gran Tierra holds interests in producing and prospective properties in Colombia and prospective properties in Ecuador. The company derives its revenue from Colombia.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.